ATHX Athersys Inc.

2.55
+0.08  (3%)
Previous Close 2.47
Open 2.45
Price To book 11.09
Market Cap 290473838
Shares 113,911,309
Volume 957,442
Short Ratio 10.39
Av. Daily Volume 964,241

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018721
  2. 8-K - Current report 171017885
  3. 8-K - Current report 17901762
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827352
  5. 8-K - Current report 17826308

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released mid April 2015. Endpoints not met. Phase 3 MASTERS-2 trial to be initiated under SPA in 2017.
Multistem
Ischemic stroke
Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
Multistem
Acute myocardial infarction

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018721
  2. 8-K - Current report 171017885
  3. 8-K - Current report 17901762
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827352
  5. 8-K - Current report 17826308
  6. DEF 14A - Other definitive proxy statements 17791593
  7. PRE 14A - Other preliminary proxy statements 17762403
  8. EFFECT - Notice of Effectiveness 17705463
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter